Arash Pakseresht

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Tirzepatide Once Weekly for the Treatment of Obesity

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial